TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab

The balance between T helper cells Th2- and Th1-related cytokines plays a key role in multiple sclerosis (MS). A shift from a Th1 towards a Th2 cytokine profile could have a beneficial effect on the clinical course of the disease. The objective of this study was to assess Th2/Th1 cytokine profile in...

Full description

Saved in:
Bibliographic Details
Published in:BMC neurology 2012-09, Vol.12 (1), p.95-95, Article 95
Main Authors: Oreja-Guevara, Celia, Ramos-Cejudo, Jaime, Aroeira, Luiz Stark, Chamorro, Beatriz, Diez-Tejedor, Exuperio
Format: Article
Language:English
Subjects:
Adjuvants, Immunologic - therapeutic use
Adult
Antibodies, Monoclonal, Humanized - therapeutic use
Biological response modifiers
Care and treatment
Cytokines
Cytokines - blood
Cytokines - immunology
Development and progression
Drug therapy
Glatiramer Acetate
Health aspects
Humans
Interferon
Interleukins
Macrophage colony stimulating factor
Macrophages
Male
Medical research
Medicine, Experimental
Multiple sclerosis
Multiple Sclerosis - blood
Multiple Sclerosis - drug therapy
Multiple Sclerosis - immunology
Natalizumab
Neurosciences
NMR
Nuclear magnetic resonance
Peptides - therapeutic use
Physiological aspects
Secondary Prevention
Statistical analysis
Th1
Th1-Th2 Balance - drug effects
Th2
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The balance between T helper cells Th2- and Th1-related cytokines plays a key role in multiple sclerosis (MS). A shift from a Th1 towards a Th2 cytokine profile could have a beneficial effect on the clinical course of the disease. The objective of this study was to assess Th2/Th1 cytokine profile in relapsing-remitting MS (RRMS) patients receiving an immunosuppressive treatment with natalizumab (NAT), or an immunomodulatory treatment with glatiramer acetate (GA) after one year of treatment. This was an observational cross-sectional study. All consecutive patients diagnosed with RRMS who had received GA or NAT for 12 months were included in the study. We determined serum levels of Th1 and Th2 cytokines (interleukin [IL]-1a, IL-1b, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-13, monocyte chemotactic protein [MCP]-1, tumor-necrosis factor [TNF]-α, interferon [IFN]-γ and granulocyte macrophage colony stimulating factor [GM-CSF]) by flow cytometry. Th2/Th1 bias was defined based on the ratio of IL-4, IL-5, IL-6 or IL-10 Th2 cytokines and proinflammatory INF-γ or TNF-α Th1 cytokines. Eleven patients under treatment with NAT and 12 patients treated with GA were evaluated. RRMS patients treated with NAT showed significantly higher levels of IL-6 (p 
ISSN:1471-2377
1471-2377
DOI:10.1186/1471-2377-12-95